Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials
Marlene L. Durand, Therese M. Kitt, Yi Song, Francisco M. Marty
Abstract
This post hoc analysis of international phase III isavuconazole trials identified 50 patients (90% immunocompromised or diabetic) with invasive fungal sinusitis (88% mucormycetes, Aspergillus) who received isavuconazole as primary (n = 33) or salvage (n = 17) therapy for a median of 82 days (range, 2-882). Overall survival was 82% at day 42 and 70% at day 84.
Topics & Concepts
Post-hoc analysisMedicinePost hocFungal sinusitisSinusitisInternal medicineClinical trialSurgeryAntifungal resistance and susceptibilityFungal Infections and StudiesOral microbiology and periodontitis research